[Evaluation of a new portable analyzer, HemoCue® Hb801, for hemoglobin point-of-care testing].

Bryan Zamorano, Yolla Sakr, Frédérique Galopin-Dubois
{"title":"[Evaluation of a new portable analyzer, HemoCue<sup>®</sup> Hb801, for hemoglobin point-of-care testing].","authors":"Bryan Zamorano, Yolla Sakr, Frédérique Galopin-Dubois","doi":"10.1684/abc.2024.1868","DOIUrl":null,"url":null,"abstract":"<p><p>The use of portable hemoglobin measuring devices is widespread. In this context, the company HemoCue® has put on the market a new device, the Hb801. It uses a whole blood absorbance measurement method and not the azidmethemoglobin measurement method used by HemoCue's older devices. We evaluated this new equipment on EDTA venous blood. Hb801 is lightweight, compact, requires a volume of 10 μL of blood and renders its result in less than a second. The repeatability and intermediate precision are close to the values expected according to Ricos, with coefficients of variation respectively for a low level of hemoglobin: 2.1% and 1.9%, for an average level: 0.8% and 1.5% and for a high level: 1.5% and 1.3%. Comparison to our laboratory reference method (XN-10 Sysmex®) and HemoCue® Hb201+ was performed on 96 samples. Bias (SD) found were: XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+: +0.17 g/dL (0.41). Clinically acceptable performance (within ± 1 g/dL of reference hemoglobin) was high: 93.8%. In the end, this device seems to us to be suitable for hemoglobin point-of-care testing.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"82 1","pages":"103-111"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1684/abc.2024.1868","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The use of portable hemoglobin measuring devices is widespread. In this context, the company HemoCue® has put on the market a new device, the Hb801. It uses a whole blood absorbance measurement method and not the azidmethemoglobin measurement method used by HemoCue's older devices. We evaluated this new equipment on EDTA venous blood. Hb801 is lightweight, compact, requires a volume of 10 μL of blood and renders its result in less than a second. The repeatability and intermediate precision are close to the values expected according to Ricos, with coefficients of variation respectively for a low level of hemoglobin: 2.1% and 1.9%, for an average level: 0.8% and 1.5% and for a high level: 1.5% and 1.3%. Comparison to our laboratory reference method (XN-10 Sysmex®) and HemoCue® Hb201+ was performed on 96 samples. Bias (SD) found were: XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+: +0.17 g/dL (0.41). Clinically acceptable performance (within ± 1 g/dL of reference hemoglobin) was high: 93.8%. In the end, this device seems to us to be suitable for hemoglobin point-of-care testing.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[评估用于血红蛋白床旁检测的新型便携式分析仪 HemoCue® Hb801]。
便携式血红蛋白测量仪的使用非常普遍。在这种情况下,HemoCue® 公司向市场推出了一款新设备 Hb801。它采用的是全血吸光度测量方法,而不是 HemoCue 旧设备使用的叠氮血红蛋白测量方法。我们对这种新设备进行了 EDTA 静脉血评估。Hb801 重量轻,结构紧凑,只需 10 μL 的血量,并能在一秒钟内得出结果。重复性和中间精度接近 Ricos 的预期值,低水平血红蛋白的变异系数分别为 2.1% 和 1.9%,平均水平为 0.8% 和 1.5%,高水平为 1.5% 和 1.3%。对 96 份样本进行了与实验室参考方法(XN-10 Sysmex®)和 HemoCue® Hb201+ 的比较。发现的偏差(SD)如下XN-10: +0.42 g/dL (0.17), HemoCue® Hb201+:+0.17 g/dL (0.41)。临床可接受的性能(参考血红蛋白在 ± 1 g/dL 以内)高达 93.8%。最后,我们认为该设备适用于血红蛋白的床旁检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Complementarity between Bayesian Internal Quality Control results management and External Quality Assessment bivariate z-score analysis: application to a concrete case study. [Can TDABC (Time-Driven Activity-Based Costing) help the NOVO hospital's medical biology laboratory to value the appropriate prescription? - Role of the biologist in reducing healthcare costs]. [Clinical associations of anti-Jo1 antibodies in a Moroccan population]. [Clinical-biological approaches to the spectrophotometric detection of oxyhemoglobin and bilirubin in CSF in the management of aneurysmal subarachnoid hemorrhage]. [Evaluation of the CellaVision® DM-1200 system for detecting and quantifying schistocytes].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1